Adjuvant Trastuzumab with or without Chemotherapy in Stage 1 pT1N0 HER2+ Breast Cancer: A National Cancer Database Analysis

Approximately 20% of all breast cancers (BC) are HER2 amplified. In the APT trial, weekly paclitaxel/trastuzumab in node negative HER2+ BC with tumors   90%. Therefore, in select patients who have contraindications for cytotoxic chemotherapy, or decline adjuvant chemotherapy altogether, adjuvant trastuzumab monotherapy appears to be a reasonable alternative.